Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 3
2004 7
2005 22
2006 16
2007 21
2008 18
2009 30
2010 27
2011 24
2012 15
2013 14
2014 18
2015 14
2016 15
2017 20
2018 15
2019 13
2020 13
2021 19
2022 19
2023 23
2024 17
2025 27
2026 13

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

392 results

Results by year

Filters applied: . Clear all
Page 1
Eszopiclone.
[No authors listed] [No authors listed] 2024 Oct 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2024 Oct 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30000277 Free Books & Documents. Review.
No data are available on the use of eszopiclone during breastfeeding. Data from the racemate, zopiclone, indicate that occasional use while breastfeeding an older infant should pose little risk to the infant. ...
No data are available on the use of eszopiclone during breastfeeding. Data from the racemate, zopiclone, indicate that occasional use …
Eszopiclone.
[No authors listed] [No authors listed] 2018 Feb 20. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2018 Feb 20. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643378 Free Books & Documents. Review.
Eszopiclone is a benzodiazepine receptor agonist that is used for the treatment of insomnia. Eszopiclone has not been implicated in causing serum enzyme elevations or clinically apparent liver injury....
Eszopiclone is a benzodiazepine receptor agonist that is used for the treatment of insomnia. Eszopiclone has not been implicat …
Eszopiclone for insomnia.
Rösner S, Englbrecht C, Wehrle R, Hajak G, Soyka M. Rösner S, et al. Cochrane Database Syst Rev. 2018 Oct 10;10(10):CD010703. doi: 10.1002/14651858.CD010703.pub2. Cochrane Database Syst Rev. 2018. PMID: 30303519 Free PMC article.
It is the aim of the review to integrate evidence from randomised controlled trials and to draw conclusions on eszopiclone's efficacy and safety profile, while taking methodological features and bias risks into consideration. ...Further, increased caution is required in el …
It is the aim of the review to integrate evidence from randomised controlled trials and to draw conclusions on eszopiclone's efficacy …
Eszopiclone for insomnia.
Melton ST, Wood JM, Kirkwood CK. Melton ST, et al. Ann Pharmacother. 2005 Oct;39(10):1659-66. doi: 10.1345/aph.1G179. Epub 2005 Aug 30. Ann Pharmacother. 2005. PMID: 16131537 Review.
OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy data, and adverse effects of eszopiclone in the treatment of transient and chronic insomnia in adult and geriatric patients. ...The results of the 6-month, open-label extension trial demonstrated that improv …
OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy data, and adverse effects of eszopiclone in the treatment of transi …
Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis.
De Crescenzo F, D'Alò GL, Ostinelli EG, Ciabattini M, Di Franco V, Watanabe N, Kurtulmus A, Tomlinson A, Mitrova Z, Foti F, Del Giovane C, Quested DJ, Cowen PJ, Barbui C, Amato L, Efthimiou O, Cipriani A. De Crescenzo F, et al. Lancet. 2022 Jul 16;400(10347):170-184. doi: 10.1016/S0140-6736(22)00878-9. Lancet. 2022. PMID: 35843245 Free article.
For long-term treatment, eszopiclone and lemborexant were more effective than placebo (eszopiclone: SMD 0.63 [95% CI 0.36-0.90; very low]; lemborexant: 0.41 [0.04-0.78; very low]) and eszopiclone was more effective than ramelteon (0.63 [0.16-1.10; very low]) …
For long-term treatment, eszopiclone and lemborexant were more effective than placebo (eszopiclone: SMD 0.63 [95% CI 0.36-0.90 …
Eszopiclone for late-life insomnia.
McCrae CS, Ross A, Stripling A, Dautovich ND. McCrae CS, et al. Clin Interv Aging. 2007;2(3):313-26. Clin Interv Aging. 2007. PMID: 18044182 Free PMC article. Review.
Clinical studies in younger adults (mean = 44 years) have shown eszopiclone can be used for 6-12 months without evidence of problems. Because the oldest participant in these longer-term trials was 69, it not known whether eszopiclone is effective for older adults [p …
Clinical studies in younger adults (mean = 44 years) have shown eszopiclone can be used for 6-12 months without evidence of problems. …
Eszopiclone: esopiclone, estorra, S-zopiclone, zopiclone--Sepracor.
[No authors listed] [No authors listed] Drugs R D. 2005;6(2):111-5. doi: 10.2165/00126839-200506020-00006. Drugs R D. 2005. PMID: 15777104 Review.
Eszopiclone is structurally unrelated to the benzodiazepines, and Sepracor (the originator of eszopiclone) has stated that the drug acts rapidly, with the duration of effect lasting up to 6 hours. ...Sepracor has been granted a US patent for eszopiclone [S-zo …
Eszopiclone is structurally unrelated to the benzodiazepines, and Sepracor (the originator of eszopiclone) has stated that the …
Eszopiclone.
Halas CJ. Halas CJ. Am J Health Syst Pharm. 2006 Jan 1;63(1):41-8. doi: 10.2146/ajhp050357. Am J Health Syst Pharm. 2006. PMID: 16373464
PURPOSE: The pharmacology, pharmacokinetics, indications, clinical efficacy, adverse effects, drug interactions, dosing, and administration of eszopiclone are discussed. SUMMARY: The pharmacology of eszopiclone is not well understood. Eszopiclone is the S-iso …
PURPOSE: The pharmacology, pharmacokinetics, indications, clinical efficacy, adverse effects, drug interactions, dosing, and administration …
Eszopiclone for the treatment of insomnia.
Scharf M. Scharf M. Expert Opin Pharmacother. 2006 Feb;7(3):345-56. doi: 10.1517/14656566.7.3.345. Expert Opin Pharmacother. 2006. PMID: 16448328 Review.

Nightly treatment with eszopiclone 1 mg effectively induced sleep in elderly patients and the 2-mg dose effectively induced and maintained sleep. ...Eszopiclone was well tolerated in clinical trials < or = 12 months duration, with no clinically significant eviden

…
Nightly treatment with eszopiclone 1 mg effectively induced sleep in elderly patients and the 2-mg dose effectively induced and maint …
Eszopiclone for the treatment of primary insomnia: a systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials.
Liang L, Huang Y, Xu R, Wei Y, Xiao L, Wang G. Liang L, et al. Sleep Med. 2019 Oct;62:6-13. doi: 10.1016/j.sleep.2019.03.016. Epub 2019 Apr 6. Sleep Med. 2019. PMID: 31518944
According to participants, intervention, comparison, outcome (PICO) criteria, studies were included that focused on: adults diagnosed with primary insomnia, aged 18-65 and > 65 years; eszopiclone for the treatment of primary insomnia; comparison were made between esz …
According to participants, intervention, comparison, outcome (PICO) criteria, studies were included that focused on: adults diagnosed with p …
392 results